Hepatitis B Virus Reading Room
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, November 20, 2015
Note: Credit Is No Longer Available
 | Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF Director, Liver Care Network and Organ Care Research Swedish Medical Center Seattle, WA |
 | Steven-Huy Han, MD, AGAF, FAASLD (Faculty) Director, Hepatology Clinical Research Center Professor of Medicine and Surgery Assistant Director, UCLA Asian Liver Center David Geffen School of Medicine University of California, Los Angeles Los Angeles, CA |
Chronic hepatitis B virus (HBV) infection is a serious liver disease that has infected 400 million people worldwide . Many clinicians are failing to identify and screen those at high risk for HBV infection who need the vaccine or appropriately selecting patients who may benefit from treatment or utilizing the agents that are recommended for prevention of advanced liver disease.
In order to meet the HHS quality measure goals for HBV, and to improve patient outcomes, these issues in clinical practice must be addressed.
This CME Outfitters Journal Club will facilitate a discussion of these issues and move clinicians toward immediate implementation of recommended therapy for appropriate patients found to have HBV infection. Using the 2011 article from Digestive Diseases and Science entitled, The Management of Chronic Hepatitis B in Asian Americans as a springboard, the 60-minute, live audio webcast will feature a discussion among authors about the key results of the research and how that translates to better patient care in practice.
The Journal Club webcast will offer a live Q&A for learners to ask questions, and exchange ideas and insights with the faculty with the goal of individualizing the learning experience and improving the management of patients with HBV.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is: Implement recommended therapy for appropriate patients with HBV infection in the next three months.
At the end of this CE activity, participants should be able to:
- Gain knowledge of treatment guidelines by The American Association for the Study of Liver Diseases and implement first-line agents in appropriate patients with hepatitis B virus infection.
- Implement identification and screening strategies in patients at high risk for hepatitis B virus infection, in order to meet quality measures published by the U.S. Department of Health & Human Services by 2016.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Review treatment guidelines and first-line agents for treating hepatitis B virus infection.
- Recognize the populations who are at high risk for hepatitis B virus infection and review screening guidelines.
Supported by an educational grant from Gilead Sciences, Inc.
Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care professionals whose scope of practice involves providing primary care for adults who have or who are at risk of developing chronic viral hepatitis B.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Activity Number: 0376-0000-14-009-L01-P (live programs)
0376-0000-14-009-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST936 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kowdley has disclosed that he has received research grants from AbbVie, Inc.; Beckman Coulter, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Ikaria, Inc.; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated. He serves as a consultant to/is on the advisory boards of AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Evidera; Gilead Sciences, Inc.; Ikaria, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Corporation; Tekmira Pharmaceuticals Corporation; and Trio Health (Paid to Virginia Mason Medical Center.
Dr. Han has disclosed that he has received research grants from Bristol Myers Squibb Company; Gilead Sciences Inc.; and Idenix Pharmaceuticals/Novartis Corporation. He serves on the speakers bureau of AbbVie Inc.; Bristol Myers Squibb Company; and Gilead Sciences Inc. He serves as a consultant to AbbVie Inc.; Bristol Myers Squibb Company; and Gilead Sciences Inc.
Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures to report.
Frances C. Daniel, MPH (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures have been obtained from CME Outfitters staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Gilead Sciences, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
JC-018-112014-47
